With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.
Cellex wins the race to get the FDA’s buy-in for a blood test to pinpoint immunity.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Silence has received an important validation, but making progress could be tough.
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
Two acquisitions of cell therapy companies could take them in almost opposite directions.
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…